GS
SAGE

GTS Securities’s Sage Therapeutics SAGE Stock Holding History

GTS Securities’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,921
Closed -$99.6K – 1658
2025
Q2 		$99.6K Buy
10,921
+798
+8% +$5.87K ﹤0.01% 1164
2025
Q1 		$80.5K Buy
+10,123
New +$74.1K ﹤0.01% 1182

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

GTS Securities's SAGE Position: Q3 2025 in Review

GTS Securities sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 10,921 shares — an estimated $99.6K sold.

GTS Securities first reported a position in SAGE in Q1 2025 and held it in 2 quarters. The position peaked at $99.6K in Q2 2025. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • GTS Securities reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • GTS Securities sold 10,921 Sage Therapeutics shares in Q3 2025, an estimated $99.6K.
  • GTS Securities first reported a position in Sage Therapeutics in Q1 2025 and held it in 2 quarters.
  • GTS Securities's Sage Therapeutics position peaked at $99.6K in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on GTS Securities's 13F filing for Q3 2025, filed 14 Nov 2025.